PARP1 and ovarian carcinoma: The recent success of PARP1 inhibitors (that block BER and SSBR) in germ-line BRCA deficient ovarian cancer [33], [34] provides evidence that targeting DNA repair is an important area for personalization of ovarian cancer therapy.